問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Radiology

Taichung Veterans General Hospital

Division of Radiology

更新時間：2023-09-19

陳蓉宣
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳蓉宣

List

23Cases

2023-09-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2022-06-01 - 2029-09-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-10-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Epcoritamab

Participate Sites
5Sites

Recruiting5Sites

2025-11-19 - 2030-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-31 - 2027-08-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Regorafenib Keytruda injection/Keytruda

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2025-12-27 - 2032-05-15

Phase III

Not yet recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

  • Condition/Disease

    Endometrial Cancer 、Malignant Solid Tumour

  • Test Drug

    Frozen crystal powder for injection Solution Infusion solution Infusion solution

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2025-04-01 - 2032-12-31

Phase III

Active
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    注射劑 注射劑

Participate Sites
5Sites

Recruiting5Sites

2021-10-01 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-12-25 - 2025-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-03-17 - 2027-01-15

Phase III

Active
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

  • Condition/Disease

    Lymphoma, Mantle-Cell

  • Test Drug

    錠劑

Participate Sites
8Sites

Recruiting8Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB